These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698 [TBL] [Abstract][Full Text] [Related]
4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates. Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351 [TBL] [Abstract][Full Text] [Related]
6. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106 [TBL] [Abstract][Full Text] [Related]
7. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484 [TBL] [Abstract][Full Text] [Related]
8. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
9. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495 [TBL] [Abstract][Full Text] [Related]
10. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
11. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259 [TBL] [Abstract][Full Text] [Related]
12. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328 [TBL] [Abstract][Full Text] [Related]
13. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154 [TBL] [Abstract][Full Text] [Related]